T. Rowe Price Associates
TVRD

T. Rowe Price Associates’s Tvardi Therapeutics TVRD Stock Holding History

T. Rowe Price Associates’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-290
Closed -$10K – 3050
2024
Q1 		$10K Hold
290
– – ﹤0.01% 2945
2023
Q4 		$8K Hold
290
– – ﹤0.01% 2892
2023
Q3 		$18K Buy
+290
New +$27.2K ﹤0.01% 2858
2021
Q4 		– Sell
-28,842
Closed -$16M – 3048
2021
Q3 		$16M Sell
28,842
-255
-0.9% -$128K ﹤0.01% 1349
2021
Q2 		$14.9M Sell
29,097
-34,772
-54% -$22M ﹤0.01% 1365
2021
Q1 		$49.9M Sell
63,869
-3,610
-5% -$2.47M 0.01% 1004
2020
Q4 		$36.8M Sell
67,479
-20,799
-24% -$10.9M ﹤0.01% 1056
2020
Q3 		$40.4M Sell
88,278
-14,383
-14% -$8.35M ﹤0.01% 944
2020
Q2 		$63.2M Sell
102,661
-4,711
-4% -$2.6M 0.01% 775
2020
Q1 		$51.1M Sell
107,372
-22,090
-17% -$12M 0.01% 778
2019
Q4 		$75.1M Buy
129,462
+661
+0.5% +$464K 0.01% 764
2019
Q3 		$84.8M Buy
128,801
+51,014
+66% +$42.4M 0.01% 675
2019
Q2 		$60.2M Buy
77,787
+7,409
+11% +$5.21M 0.01% 813
2019
Q1 		$49.7M Buy
70,378
+3,281
+5% +$1.96M 0.01% 882
2018
Q4 		$31.4M Sell
67,097
-48
-0.1% -$31K 0.01% 988
2018
Q3 		$57.9M Buy
67,145
+54,030
+412% +$39M 0.01% 860
2018
Q2 		$9.04M Sell
13,115
-198
-1% -$101K ﹤0.01% 1363
2018
Q1 		$5.93M Buy
13,313
+2
+0% +$970 ﹤0.01% 1412
2017
Q4 		$5.87M Buy
13,311
+637
+5% +$290K ﹤0.01% 1415
2017
Q3 		$6.25M Sell
12,674
-452
-3% -$226K ﹤0.01% 1406
2017
Q2 		$7.27M Buy
13,126
+5,035
+62% +$3.19M ﹤0.01% 1364
2017
Q1 		$5.36M Buy
+8,091
New +$4.32M ﹤0.01% 1423
2015
Q2 		– Sell
-7,045
Closed -$2.55M – 2561
2015
Q1 		$2.55M Hold
7,045
– – ﹤0.01% 1551
2014
Q4 		$2.53M Sell
7,045
-7
-0.1% -$2.25K ﹤0.01% 1543
2014
Q3 		$2.13M Buy
7,052
+6,763
+2,340% +$2.78M ﹤0.01% 1569
2014
Q2 		$177K Sell
289
-4,034
-93% -$2.17M ﹤0.01% 2378
2014
Q1 		$2.9M Buy
+4,323
New +$2.56M ﹤0.01% 1503

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

T. Rowe Price Associates's TVRD Position: Q2 2024 in Review

T. Rowe Price Associates sold out of Tvardi Therapeutics (TVRD) in Q2 2024, closing a stake of 290 shares — an estimated $10K sold.

T. Rowe Price Associates first reported a position in TVRD in Q1 2014 and held it in 27 quarters. The position peaked at $84.8M in Q3 2019. 79 funds tracked by Wall St. Rank hold TVRD as of Q2 2024.

  • T. Rowe Price Associates reported no remaining Tvardi Therapeutics position as of Q2 2024 after selling out during the quarter.
  • T. Rowe Price Associates sold 290 Tvardi Therapeutics shares in Q2 2024, an estimated $10K.
  • T. Rowe Price Associates first reported a position in Tvardi Therapeutics in Q1 2014 and held it in 27 quarters.
  • T. Rowe Price Associates's Tvardi Therapeutics position peaked at $84.8M in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q2 2024.

Based on T. Rowe Price Associates's 13F filing for Q2 2024, filed 14 Aug 2024.